t
Avacta Group PLC announced on February 18, 2026, that its CEO, Christina Coughlin, and CFO, Brian Hahn, will participate in the 46th Annual TD Cowen Health Care Conference. This participation will occur in Boston on March 3, 2026, where they are scheduled to host investor meetings and give a live presentation at 9:10 AM ET.
Avacta to Participate in Investor Conference in March 2026
LONDON and PHILADELPHIA - February 18, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announces the executive management team will participate in the TD Cowen Investor Conference in March.
Christina Coughlin, CEO and Brian Hahn, CFO of Avacta, will participate in the 46th Annual TD Cowen Health Care Conference in Boston on March 3, 2026. The company will host investor meetings throughout the day, with a live Company presentation at 9:10 AM ET. Investors interested in accessing the Company's presentation may view the replay of the presentation, which will be available after the event on the Investor Resources | Avacta Therapeutics site.
-Ends-
For further information from Avacta, please contact:
|
Avacta Group plc Christina Coughlin, Chief Executive Officer
|
via Cohesion Bureau |
|
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance
|
|
|
Zeus (Broker) James Hornigold / George Duxberry / Dominic King
|
|
|
Cohesion Bureau (Communications) Richard Jarvis / Chris Maggos
|
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.
Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.